Scholarlink

<p>Hyperlipidemia and dyslipidemia make a substantial contribution to cardiovascular morbidity and mortality in people with diabetes mellitus. Pharmacotherapy with statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and bempedoic acid has convincingly been shown to reduce the cardiovascular risk of people with diabetes. The present article presents the treatment recommendations of the Austrian Diabetes Association for the use of lipid-lowering drugs in people with diabetes according to current scientific evidence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lipide: Diagnostik und Therapie bei Diabetes mellitus (Update 2026)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月30日

查看全文
  • Thomas C. Wascher,
  • Bernhard Paulweber,
  • Hermann Toplak,
  • Christoph H. Saely,
  • Heinz Drexel,
  • Bernhard Föger,
  • Friedrich Hoppichler,
  • Thomas Stulnig,
  • Harald Stingl,
  • Florian Höllerl,
  • Martin Clodi

摘要

Hyperlipidemia and dyslipidemia make a substantial contribution to cardiovascular morbidity and mortality in people with diabetes mellitus. Pharmacotherapy with statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and bempedoic acid has convincingly been shown to reduce the cardiovascular risk of people with diabetes. The present article presents the treatment recommendations of the Austrian Diabetes Association for the use of lipid-lowering drugs in people with diabetes according to current scientific evidence.